Preliminary Study on the Expression and the Clinical Significance of CD133 in Peripheral Blood of Patients with Gastric Adenocarcinoma

Table 2

Multivariate risk analysis on the correlation of the BSV of preoperative CD133 mRNA in PBMCs with clinicopathological features.

Parameters	𝐵	S.E.	Wald	df	Sig.	Exp(𝐵)	95.0% of CI
							Lower	Upper
Gender	−0.979	0.929	1.109	1	0.292	0.376	0.061	2.323
Size of tumor	−0.550	0.840	0.429	1	0.513	0.577	0.111	2.995
Lauren type	−2.268	1.393	2.651	1	0.103	0.104	0.007	1.587
Histological type	3.653	1.439	8.532	2	0.074	0.120	0.012	0.877
Vascular invasion	−1.206	1.124	1.150	1	0.284	0.299	0.033	2.713
Lymphatic vessel invasion	0.789	1.291	0.373	1	0.541	0.454	0.036	5.707
Invasive depth	3.531	1.561	0.116	1	0.034	1.700	0.080	36.268
Lymph node metastasis	0.785	1.560	0.254	1	0.615	2.193	0.013	1.293
TNM stage	0.915	2.266	0.163	1	0.686	2.497	0.029	211.924
CD133 mRNA in primary tissue	5.846	3.292	3.154	1	0.076	0.003	0.000	1.833
CD133 protein expressed in primary tissue	0.943	1.049	0.809	1	0.369	2.568	0.329	20.058
MLR	0.101	0.058	3.033	1	0.082	0.904	0.807	1.013
Metastatic lymph node number	0.647	0.290	4.968	1	0.026	1.190	1.081	3.375
Dissected lymph node number	−0.055	0.082	0.449	1	0.503	0.947	0.806	1.111